LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Sanofi

Sanofi

Fermé

57.74 -0.89

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

57.61

Max

57.79

Chiffres clés
By Trading Economics
Revenu	-20M 1.1B
Ventes	262M 11B
P/E Moyenne du Secteur	25.1 103.001
BPA	0.455
Marge bénéficiaire	9.78
EBITDA	-136M 2B

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+0.47 upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	142B
Ouverture précédente	58.63
Clôture précédente	57.74

Score Technique

By Trading Central

Confiance

Neutral Evidence

56.21 / 58.15 Support & Résistance

Sanofi Graphique

Actualités Associées

25 juil. 2024, 05:44 UTC

Résultats

Sanofi Raises Guidance After Profit, Sales Beat

4 juil. 2024, 06:44 UTC

Acquisitions, Fusions, Rachats

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27 juin 2024, 10:54 UTC

Principaux Mouvements du Marché

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

26 juin 2024, 07:15 UTC

Acquisitions, Fusions, Rachats

Sanofi Starts Bidding Process to Sell Consumer Health Division, Bloomberg Reports

13 mai 2024, 18:14 UTC

Principaux Mouvements du Marché

Novavax Shares Pop Another 50% Following Sanofi Deal

25 juil. 2024, 13:20 UTC

Résultats

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25 juil. 2024, 11:46 UTC

Market Talk

Résultats

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25 juil. 2024, 11:23 UTC

Market Talk

Résultats

Sanofi Results Are Positive -- Market Talk

25 juil. 2024, 05:33 UTC

Résultats

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25 juil. 2024, 05:33 UTC

Résultats

Sanofi 2Q Sales EUR10.745B

25 juil. 2024, 05:30 UTC

Résultats

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25 juil. 2024, 05:30 UTC

Résultats

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25 juil. 2024, 05:30 UTC

Résultats

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25 juil. 2024, 05:30 UTC

Résultats

Sanofi 2Q Net Pft EUR1.11B

25 juil. 2024, 05:30 UTC

Résultats

Sanofi Raises 2024 View

25 juil. 2024, 05:30 UTC

Résultats

Sanofi 2Q Business Operating Income EUR2.81B

9 juil. 2024, 09:05 UTC

Actualités

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3 juil. 2024, 14:18 UTC

Acquisitions, Fusions, Rachats

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

27 juin 2024, 10:39 UTC

Principaux Mouvements du Marché

Vigil Neuroscience Shares Soar on $40M Sanofi Investment

27 juin 2024, 06:08 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience Is a Clinical-Stage Biotechnology Company >VIGL

27 juin 2024, 06:08 UTC

Acquisitions, Fusions, Rachats

Vigil: Program Includes Clinical Candidate VG-3927, Being Evaluated in Phase 1 Study for Alzheimer's >VIGL

27 juin 2024, 06:08 UTC

Acquisitions, Fusions, Rachats

Vigil: To Grant Sanofi Exclusive Right of First Negotiation for License of Small Molecule TREM2 Agonist Program >VIGL

27 juin 2024, 06:07 UTC

Acquisitions, Fusions, Rachats

Vigil Expects Proceeds to Extend Cash Runway Into 2026 >VIGL

27 juin 2024, 06:06 UTC

Acquisitions, Fusions, Rachats

Vigil: Will Use Proceeds to Fund R&D Activities >VIGL

27 juin 2024, 06:06 UTC

Acquisitions, Fusions, Rachats

Vigil: Each Share Convertible Into 10 Shares of Common Stock >VIGL

27 juin 2024, 06:06 UTC

Acquisitions, Fusions, Rachats

Vigil: Sanofi Will Purchase 537,634 of Company's Series A Non-Voting Preferred Shares >VIGL

30 mai 2024, 13:10 UTC

Acquisitions, Fusions, Rachats

Sanofi: Acquisition Relates to Human Protein to Treat Patients With Rare Hereditary Diseases

30 mai 2024, 13:08 UTC

Acquisitions, Fusions, Rachats

Sanofi Completes Acquisition of Biotech Inhibrx

30 mai 2024, 13:01 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi Completes Acquisition Of Inhibrx, Inc. >SAN.FR

10 mai 2024, 22:38 UTC

Acquisitions, Fusions, Rachats

Inhibrx: Following Inhibrx Merger With Sanofi, Inhibrx Biosciences to Trade Under INBX

Comparaison

Variation de prix

Sanofi prévision

Objectif de Prix

By TipRanks

0.47% hausse

Prévisions sur 12 Mois

Moyen 58 USD 0.47%

Haut 60 USD

Bas 56 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

56.21 / 58.15Support & Résistance

The bullish and bearish events are balanced.

All events are bullish.

Recent bullish events outweigh bearish events.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

À Propos Sanofi

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.